FRRS1L: A Promising Drug Target for Cancer and Neurodegenerative Diseases

Target Name: FRRS1L

NCBI ID: G23732

FRRS1L

FRRS1L: A Promising Drug Target for Cancer and Neurodegenerative Diseases

FRRS1L (Forskolin-Inducible gene 1-like), also known as CG-6, is a protein that is expressed in various tissues and organs, including brain, heart, kidneys, and pancreas. It is a potent regulator of cell proliferation and has been linked to several diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the most promising aspects of FRRS1L is its potential as a drug target. Its unique mechanism of action, as well as its broad distribution in the body, make it an attractive target for drug developers. FRRS1L has been shown to play a role in a variety of biological processes, including cell signaling, cell division, and tissue repair. Its expression has also been linked to several diseases, including cancer, neurodegenerative diseases, and developmental disorders.

FRRS1L has been shown to promote cell proliferation by activating several signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, maintenance, and repair, and is a key regulator of tissue growth and development. By activating TGF-β, FRRS1L has been shown to promote the formation of new blood vessels, which can lead to the development of tumors.

FRRS1L has also been shown to play a role in cell division. It is a transcription factor that is involved in the regulation of gene expression, and has been shown to promote the growth and proliferation of cancer cells. Its expression has also been linked to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

In addition to its role in cell proliferation and cell division, FRRS1L has also been shown to play a role in tissue repair. It is a transcription factor that is involved in the regulation of cell survival and has been shown to promote tissue repair after injury or disease. Its expression has also been linked to the development of diseases such as cancer, neurodegenerative diseases, and developmental disorders.

FRRS1L has a wide distribution in the body and has been shown to be expressed in a variety of tissues and organs, including brain, heart, kidneys, and pancreas. Its expression has also been linked to several diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the most promising aspects of FRRS1L is its potential as a drug target. Its unique mechanism of action, as well as its broad distribution in the body, make it an attractive target for drug developers. FRRS1L has been shown to play a role in a variety of biological processes, including cell signaling, cell division, and tissue repair. Its expression has also been linked to several diseases, including cancer, neurodegenerative diseases, and developmental disorders.

FRRS1L has also been shown to promote cell proliferation by activating several signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, maintenance, and repair, and is a key regulator of tissue growth and development. By activating TGF-β, FRRS1L has been shown to promote the formation of new blood vessels, which can lead to the development of tumors.

FRRS1L has also been shown to play a role in cell division. It is a transcription factor that is involved in the regulation of gene expression, and has been shown to promote the growth and proliferation of cancer cells. Its expression has also been linked to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

In addition to its role in cell proliferation and cell division, FRRS1L has also been shown to play

Protein Name: Ferric Chelate Reductase 1 Like

Functions: Important modulator of glutamate signaling pathway

The "FRRS1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRRS1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets